<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02663518</url>
  </required_header>
  <id_info>
    <org_study_id>TTI-621-01</org_study_id>
    <nct_id>NCT02663518</nct_id>
  </id_info>
  <brief_title>A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors</brief_title>
  <official_title>A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trillium Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trillium Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, open-label, phase 1a/1b trial of TTI-621 in subjects with relapsed or refractory&#xD;
      hematologic malignancies and selected solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies&#xD;
      and selected solid tumors.&#xD;
&#xD;
      TTI-621 (SIRPαFc) is a soluble recombinant fusion protein created by directly linking the&#xD;
      sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of&#xD;
      human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from&#xD;
      delivering an inhibitory &quot;do not eat&quot; (anti phagocytic) signal to macrophages.&#xD;
&#xD;
      This trial will be conducted in 2 phases and 4 parts: Phase 1a Part 1 (escalation phase) and&#xD;
      Phase 1b Parts 2-4 (expansion phase).&#xD;
&#xD;
      In the dose Escalation Phase (phase 1a Part 1), subjects with lymphoma will be enrolled in&#xD;
      sequential dose cohorts to receive TTI-621 to characterize safety, tolerability,&#xD;
      pharmacokinetics, and the maximum-tolerated dose (MTD).&#xD;
&#xD;
      In the Expansion Phase (phase 1b Parts 2-4), TTI-621 will be given to subjects with a variety&#xD;
      of hematologic malignancies and selected solid tumors to further define safety and to&#xD;
      characterize efficacy. In the Expansion Phase Part 2, the safety and efficacy of TTI-621 will&#xD;
      also be assessed when it is given in combination with other anti-cancer drugs. The dose of&#xD;
      TTI-621 to be delivered in the Expansion Phase Parts 2-3 of the study may be increased or&#xD;
      decreased based on the subject's tolerability and on the subject's response to treatment.&#xD;
&#xD;
      In the phase 1b dose optimization of the study (Part 4), further dose escalation of TTI-621,&#xD;
      beyond the dose determined during phase 1a dose escalation, will be pursued in patients with&#xD;
      relapsed and/or refractory CTCL following a 3+3 escalation design and using a revised DLT&#xD;
      criteria to further evaluate the safety and tolerability of TTI-621 at dose levels higher&#xD;
      than the initially recommended phase 1b Parts 2-3.&#xD;
&#xD;
      Secondary objectives include further characterization of the pharmacokinetics,&#xD;
      pharmacodynamics, and development of ADA; and to gain preliminary evidence of the anti-tumor&#xD;
      activity of TTI-621 in subjects with a variety of hematologic malignancies and selected solid&#xD;
      tumors. In addition, the safety of TTI-621 will be evaluated in combination with other&#xD;
      anti-cancer agents.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>42 months</time_frame>
    <description>Safety and tolerability of TTI-621 when given alone and in combination with other anti-cancer agents to subjects with a variety of hematologic malignancies and with selected solid tumors, and to evaluate the safety of a standardized intra-subject TTI-621 dose intensification schedule.&#xD;
Part 4: To further evaluate the safety and tolerability of TTI-621 at dose levels higher than the initially recommended phase 1b Parts 2 and 3 dose and to reassess the MTD and/or recommended phase 2 dose per revised DLT criteria following a 3+3 dose escalation schema.</description>
  </primary_outcome>
  <number_of_arms>17</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Hematologic Malignancies</condition>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>TTI-621 Escalation Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Escalation Phase will include multiple doses of TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indolent B-Cell Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aggressive B-Cell Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T-Cell Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hodgkin Lymphoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic Lymphocytic Leukemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute Lymphoblastic Leukemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Myeloma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute Myeloid Leukemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Myelodysplastic Syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Myeloproliferative Neoplasms</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Small Cell Lung Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy expansion cohort with TTI-621 plus Rituximab for CD20 positive malignancies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nivolumab Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy expansion cohort with TTI-621 plus Nivolumab for Hodgkin Lymphoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cutaneous T-Cell Lymphoma (CTCL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peripheral T-Cell Lymphoma (PTCL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion cohort with TTI-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 4: Cutaneous T-Cell Lymphoma (CTCL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Monotherapy expansion Part 4 (Dose Optimization) cohort with TTI-621</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTI-621</intervention_name>
    <description>Monotherapy</description>
    <arm_group_label>Acute Lymphoblastic Leukemia</arm_group_label>
    <arm_group_label>Acute Myeloid Leukemia</arm_group_label>
    <arm_group_label>Aggressive B-Cell Lymphoma</arm_group_label>
    <arm_group_label>Chronic Lymphocytic Leukemia</arm_group_label>
    <arm_group_label>Cutaneous T-Cell Lymphoma (CTCL)</arm_group_label>
    <arm_group_label>Hodgkin Lymphoma</arm_group_label>
    <arm_group_label>Indolent B-Cell Lymphoma</arm_group_label>
    <arm_group_label>Multiple Myeloma</arm_group_label>
    <arm_group_label>Myelodysplastic Syndrome</arm_group_label>
    <arm_group_label>Myeloproliferative Neoplasms</arm_group_label>
    <arm_group_label>Part 4: Cutaneous T-Cell Lymphoma (CTCL)</arm_group_label>
    <arm_group_label>Peripheral T-Cell Lymphoma (PTCL)</arm_group_label>
    <arm_group_label>Small Cell Lung Cancer</arm_group_label>
    <arm_group_label>T-Cell Lymphoma</arm_group_label>
    <arm_group_label>TTI-621 Escalation Phase</arm_group_label>
    <other_name>SIRPαFc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTI-621 plus Rituximab</intervention_name>
    <description>Combination therapy</description>
    <arm_group_label>Rituximab Combination</arm_group_label>
    <other_name>TTI-621 plus Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTI-621 plus Nivolumab</intervention_name>
    <description>Combination therapy</description>
    <arm_group_label>Nivolumab Combination</arm_group_label>
    <other_name>TTI-621 plus Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Advanced measurable malignancy&#xD;
&#xD;
          2. Adequate hematologic status&#xD;
&#xD;
          3. Relapsed or are refractory following at least 2 prior systemic therapeutic attempts (1&#xD;
             prior systemic attempt for PTCL). For CTCL, extracorporal photochemotherapy (ECP) will&#xD;
             be considered a systemic therapy. Local radiation and topical agents are not systemic&#xD;
             therapies.&#xD;
&#xD;
          4. Adequate coagulation function&#xD;
&#xD;
          5. Adequate hepatic function&#xD;
&#xD;
          6. Adequate renal function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known, current central nervous system disease involvement or untreated brain&#xD;
             metastases&#xD;
&#xD;
          2. Allogeneic transplant within 30 days prior to the planned start of treatment or&#xD;
             subjects with active graft-vs-host disease with the exception of Grade 1 skin&#xD;
             involvement&#xD;
&#xD;
          3. History of hemolytic anemia or bleeding diathesis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amani Ammari</last_name>
    <email>amani@trilliumtherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathleen Large</last_name>
    <email>kathleen2@trilliumtherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Lyons</last_name>
      <phone>904-953-6826</phone>
      <email>Lyons.Christopher@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>James Foran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elyce Turba</last_name>
      <phone>813-745-1706</phone>
      <email>elyce.turba@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Lubomir Sokol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Ansell</last_name>
      <phone>855-776-0015</phone>
      <email>ansell.stephen@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Ansell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack Meridian Health John Theurer Cancer Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Yannotti</last_name>
      <phone>551-996-5168</phone>
      <email>Kara.Yannotti@hackensackmeridian.org</email>
    </contact>
    <investigator>
      <last_name>Tatyana Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Mesidor</last_name>
      <phone>212-263-4403</phone>
      <email>Antoine.Mesidor@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Catherine Diefenbach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia Univeristy</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Freddy J. Loffredo</last_name>
      <email>fl2156@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Larisa Geskin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Horwitz</last_name>
      <email>horwitzs@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Steven Horwitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Monette</last_name>
      <phone>503-494-9455</phone>
      <email>monette@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Craig Okada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue McCann</last_name>
      <phone>412-864-3681</phone>
      <email>mccannsa@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Oleg Akilov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>877-691-7274</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Ian Flinn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Auris Huen, MD</last_name>
      <phone>713-745-1113</phone>
      <email>aohuen@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Auris Huen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington - Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1H6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diego Villa</last_name>
      <phone>604-877-6000</phone>
      <email>dvilla@bccancer.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Diego Villa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Center</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Philip</last_name>
      <phone>416-581-7823</phone>
      <email>Lindsay.Philip@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Vishal Kukreti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clincancerres.aacrjournals.org/content/clincanres/early/2017/01/09/1078-0432.CCR-16-1700.full.pdf</url>
    <description>TTI-621: a novel innate immune checkpoint inhibitor</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 19, 2016</study_first_submitted>
  <study_first_submitted_qc>January 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2016</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T-Cell</keyword>
  <keyword>CTCL</keyword>
  <keyword>PTCL</keyword>
  <keyword>ALL</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>TTI-621</keyword>
  <keyword>Solid Tumor</keyword>
  <keyword>Hematologic Malignancies</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Cutaneous T-Cell Lymphoma</keyword>
  <keyword>Peripheral T-Cell Lymphoma</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>CD47</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

